-+ 0.00%
-+ 0.00%
-+ 0.00%

Lexeo to present new gene therapy and AAV manufacturing data at ASGCT meeting

PUBT·04/27/2026 21:15:20
Listen to the news
Lexeo to present new gene therapy and AAV manufacturing data at ASGCT meeting
  • Lexeo Therapeutics will present new data on cardiac gene therapy programs, neurologic work in Friedreich ataxia, and AAV manufacturing at ASGCT Annual Meeting in Boston on May 11-15, 2026.
  • Clinical update on LX2006 gene therapy for Friedreich ataxia cardiomyopathy is scheduled for May 13, 2026.
  • Preclinical TNNI3 cardiomyopathy gene therapy presentation is scheduled for May 12, 2026.
  • Manufacturing-focused presentations on AAVrh.10 process comparability, scale-up, and sequencing in release testing are scheduled for May 14-15, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexeo Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604271715PRIMZONEFULLFEED9707958) on April 27, 2026, and is solely responsible for the information contained therein.